Form 4 for HALO HALOZYME THERAPEUTICS, INC.
Accepted 2025-02-24 00:00:00 ET · period of report 2025-02-23 · accession 0001415889-25-005299 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-24 | 2025-02-23 | HALO | LaBrosse Nicole | SVP, CFO | F - Tax | $57.75 | -3,601 | 31.9K | -10% | -$208.0K |
| D | 2025-02-24 | 2025-02-23 | HALO | LaBrosse Nicole | SVP, CFO | M - OptEx | $0.00 | +6,688 | 35.5K | +23% | $0 |
| D | 2025-02-24 | 2025-02-23 | HALO | LaBrosse Nicole | SVP, CFO | M - OptEx | $0.00 | -6,688 | 20.1K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-23 | F | D | 3,601 | $57.75 | 31,900 | D | — | — | (F1) The reported disposition of 3,601 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. |
| 2 | Common | Common Stock | 2025-02-23 | M | A | 6,688 | $0.00 | 35,501 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2025-02-23 | M | D | 6,688 | $0.00 | 20,063 | D | $0.00 · — to — | 6,688 Common Stock | (F2) This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. |